That number is not just large in absolute terms, it is the largest weight-loss signal ever reported in a randomized Phase 3 trial of a GLP-1-class compound, and it arrived with additional secondary findings that reframe what "GLP-1 therapy" could eventually mean: a 75.8% reduction in osteoarthritis pain, a roughly 20% drop in LDL cholesterol, and a 72% reversal rate of prediabetes to normoglycemia in the affected subpopulation
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
SURMOUNT-1 and STEP-1: Obesity-Specific Trials SURMOUNT-1 (Tirzepatide for Obesity, NEJM 2022): At the maximum 15 mg dose, participants without diabetes lost an average of 22.5% of their body weight over 72 weeks approximately 51 lbs for a 225-lb person
CB1 and GLP-1 receptors cross talk provides new therapies for obesity
Compounders also might see a tailwind from the current political environment
We learned that GLP-1 medications are effective and safe. Because of this WeightWatchers bought Sequence and turned it into WeightWatchers Clinic We wanted to do what was best for our members, which included acquiring Sequence and offering weight loss medications alongside our comprehensive behavioral solution. according to the brand representative